about
Physiologic Assessment of Coronary Artery Disease: Focus on Fractional Flow ReserveRegadenoson use in patients with chronic obstructive pulmonary disease: the state of current knowledgeRecent developments in adenosine receptor ligands and their potential as novel drugsRepeatability and variability of myocardial perfusion imaging techniques in mice: Comparison of arterial spin labeling and first-pass contrast-enhanced MRI.Chest pain: coronary CT in the ER.Accelerated dual-contrast first-pass perfusion MRI of the mouse heart: development and application to diet-induced obese miceAssessment of stable coronary artery disease by cardiovascular magnetic resonance imaging: Current and emerging techniques.The immunosuppressive role of adenosine A2A receptors in ischemia reperfusion injury and islet transplantation.SPECT imaging for detecting coronary artery disease and determining prognosis by noninvasive assessment of myocardial perfusion and myocardial viability.Effect of caffeine on SPECT myocardial perfusion imaging during regadenoson pharmacologic stress: a prospective, randomized, multicenter study.Pharmacological Activity and Clinical Use of PDRN.Transient Ischemic Dilation Ratio in Regadenoson, Single Isotope Gated Single-photon Emission Computed Tomography Myocardial Perfusion Imaging.Assessment of myocardial perfusion and function with PET and PET/CT.International Union of Basic and Clinical Pharmacology. LXXXI. Nomenclature and classification of adenosine receptors--an updateMolecular docking screening using agonist-bound GPCR structures: probing the A2A adenosine receptor.The discovery of a selective and potent A2a agonist with extended lung retention.A randomized, double-blind, placebo-controlled study of the safety and tolerance of regadenoson in subjects with stage 3 or 4 chronic kidney disease.The effect of obesity on regadenoson-induced myocardial hyperemia: a quantitative magnetic resonance imaging study.Safety of guidewire-based measurement of fractional flow reserve and the index of microvascular resistance using intravenous adenosine in patients with acute or recent myocardial infarction.Safety and feasibility of regadenoson use for suboptimal heart rate response during symptom-limited standard Bruce exercise stress test.Considerations when measuring myocardial perfusion reserve by cardiovascular magnetic resonance using regadenosonAMPD1 polymorphism and response to regadenosonRegadenoson and adenosine are equivalent vasodilators and are superior than dipyridamole- a study of first pass quantitative perfusion cardiovascular magnetic resonance.Prognostic value of normal regadenoson stress perfusion cardiovascular magnetic resonance.Assessment of global myocardial perfusion reserve using cardiovascular magnetic resonance of coronary sinus flow at 3 Tesla.Tools for cardiovascular magnetic resonance imaging.Selective adenosine agonists and myocardial perfusion imaging.Stress CT perfusion: coupling coronary anatomy with physiology.Regadenoson: a focused update.Cardiac MR perfusion imaging: where we are.Serious and potentially life threatening complications of cardiac stress testing: Physiological mechanisms and management strategies.Imaging of the heart: historical perspective and recent advances.The reproducibility and prognostic value of serial measurements of heart rate response to regadenoson during myocardial perfusion imaging.Safety issues of compounds acting on adenosinergic signalling.Safety and tolerability of regadenoson in 514 SPECT MPI patients with and without coronary artery disease and submaximal exercise heart rate response.Safety and tolerability of regadenoson for myocardial perfusion imaging - first Danish experience.Effect of changes in perfusion defect size during serial regadenoson myocardial perfusion imaging on cardiovascular outcomes in high-risk patients.Comparison of the prognostic value of regadenoson and adenosine myocardial perfusion imaging.Safety of regadenoson in patients with end-stage liver disease.A strategy of symptom-limited exercise with regadenoson-as-needed for stress myocardial perfusion imaging: a randomized controlled trial.
P2860
Q26748665-551056A0-B00C-47DF-9A37-828FC44C15E4Q26829779-2B782B33-83EE-439D-82F8-75B642405E2FQ27687253-FBE8787B-FE35-4168-AA1B-A9CE5684396CQ30278993-FF44CF1B-3065-4662-A02B-32A899132012Q30357516-B69F892E-9CE8-4B5D-9CAC-7EB1628CCCD3Q30360543-3FCC9491-78CD-4352-B926-BB02B1D50B48Q30361261-823782D6-775B-43D9-963E-4C98CD9F3111Q30409961-4776B601-43E8-4E4D-A839-D8D54C761B30Q30453814-A1651B69-95E2-453E-8FE7-ECD3D756D88EQ33561287-267AD3FC-9F3D-4FF4-8382-2996738B7793Q33603413-B4CAF26C-C35F-4925-97E2-8F0ED4BBF89DQ33767661-83262B56-2D4D-4585-908A-9DB5D40489FAQ33854906-CA53CB67-FA80-4C22-AD8E-9DD22619DDE2Q34701303-B843A7B1-10DF-43E2-8BD7-76771DD17FE9Q35549895-9DCE466C-71B1-42C7-A527-A903E3F8BBCBQ35822325-53351E3D-310C-4368-BB43-4C8F781CEAB9Q35904476-56DAAF8F-6933-45E1-88C2-D62A7960DE85Q36296064-9584898D-B77B-4C4E-AE48-EEF6405AC487Q36345768-29068593-09DA-41CF-A27B-7826A59C3B1BQ36497022-39682E23-92A4-44B5-B186-E8351777B2A3Q36555852-30BB720D-6B74-4C44-B2C5-CE29415B9E67Q36783584-3EB01875-DAAF-4ED1-B644-EA603B1DA99CQ37364858-A867AE9E-4D17-4B0D-AC80-83F64D5AF2E4Q37425510-7D27C17C-C5C9-472F-9C13-0958DBB0A536Q37688871-2F334809-341A-4E1A-8A10-A049FB17F090Q37717680-BC49FC3D-E1DA-4933-B629-04BF06B8C245Q37963279-48BCE86D-3427-4F8D-86DD-B8E348D3CD9BQ37997961-E6503DC4-0B89-4BEF-89AC-BD112A017B93Q38066403-4E39CE44-81B2-4AD2-B29C-2E880F341C87Q38230320-A48AB8CE-AF2D-4573-ACA5-671F8907155EQ38480969-B45ECF19-A20D-43BF-86FF-E3354747C8CAQ38662875-7E848CB1-F308-4B7F-9AB4-CD2234397748Q38808550-1DE42765-EC76-4243-8A2C-C54CF42C8A5BQ38843185-4C732E37-8313-4A37-8856-1656F10169EAQ39508932-D30237E5-C954-4D4B-B2A1-C6B75A33DA98Q40865264-06798FEC-5448-4FEE-8D36-1D45E0B4B052Q40896705-DB93C0DC-C98B-42BE-A43F-E1A220BB3B3FQ40925997-3FC79597-7FB4-41ED-BFF5-924298065C62Q43824973-E66A3B06-F51F-41E7-93F9-C5F58DB34515Q45354603-C82DC2B2-6FF4-4593-8918-6261B2CD640B
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on September 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Regadenoson: a new myocardial stress agent.
@en
Regadenoson: a new myocardial stress agent.
@nl
type
label
Regadenoson: a new myocardial stress agent.
@en
Regadenoson: a new myocardial stress agent.
@nl
prefLabel
Regadenoson: a new myocardial stress agent.
@en
Regadenoson: a new myocardial stress agent.
@nl
P1476
Regadenoson: a new myocardial stress agent.
@en
P2093
Ami E Iskandrian
Wael Al Jaroudi
P304
P356
10.1016/J.JACC.2009.04.089
P407
P577
2009-09-01T00:00:00Z